Subtopic Deep Dive
Allogeneic Stem Cell Transplantation in Myeloproliferative Neoplasms
Research Guide
What is Allogeneic Stem Cell Transplantation in Myeloproliferative Neoplasms?
Allogeneic stem cell transplantation (allo-SCT) is the only curative therapy for high-risk myeloproliferative neoplasms (MPNs), particularly those transforming to acute leukemia, involving donor hematopoietic stem cell replacement after conditioning.
Allo-SCT targets MPNs like primary myelofibrosis and post-MPN acute myeloid leukemia (AML) through graft-versus-leukemia effects. Donor selection, conditioning regimens, and prognostic models guide eligibility (Passamonti et al., 2009; 951 citations). Over 10,000 citations across WHO classifications define MPN diagnostic criteria for transplant decisions (Arber et al., 2016; 9991 citations).
Why It Matters
Allo-SCT provides potential cure for transforming MPNs, improving survival in high-risk primary myelofibrosis patients identified by IPSS/DIPSS models (Passamonti et al., 2009). European LeukemiaNet guidelines recommend allo-SCT for intermediate-2/high-risk cases or post-polycythemia vera/essential thrombocythemia myelofibrosis (Barbui et al., 2011; 825 citations). In secondary AML from MPNs, allo-SCT outcomes differ from de novo AML, informing therapy-related risk stratification (Østgård et al., 2015; 433 citations). These applications guide clinical trial design and personalized treatment in ~10-20% of advanced MPN cases.
Key Research Challenges
Donor Selection Optimization
Matching HLA and considering haploidentical donors remain critical for MPN allo-SCT success. Outcomes vary with donor type in high-risk cohorts (Barbui et al., 2011). No provided papers quantify exact mismatch impacts.
Conditioning Regimen Toxicity
Balancing myeloablative versus reduced-intensity conditioning affects relapse and non-relapse mortality in MPN transformations. IPSS-high patients require tailored intensity (Passamonti et al., 2009). Optimal regimens lack consensus.
Graft-Versus-Leukemia Effect Prediction
Quantifying GvL in JAK2-mutated MPNs versus leukemia transformation is challenging. Molecular markers like ASXL1 influence post-transplant relapse (Tefferi, 2010; 520 citations). Prognostic models need refinement.
Essential Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · 2016 · Blood · 10.0K citations
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identi...
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman, Jüergen Thiele, Daniel A. Arber et al. · 2009 · Blood · 4.4K citations
Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the...
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury, Éric Solary, Oussama Abla et al. · 2022 · Leukemia · 3.5K citations
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu et al. · 2021 · Signal Transduction and Targeted Therapy · 2.2K citations
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti, Francisco Cervantes, Alessandro M. Vannucchi et al. · 2009 · Blood · 951 citations
Abstract Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 × 109/L, peripheral blood blasts 1% or higher, and constitutional symptoms ha...
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård et al. · 2011 · Journal of Clinical Oncology · 825 citations
We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, fi...
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Sally Thomas, John A. Snowden, Martin P. Zeidler et al. · 2015 · British Journal of Cancer · 626 citations
Reading Guide
Foundational Papers
Start with Vardiman et al. (2009; 4374 citations) for WHO MPN classification basics, then Passamonti et al. (2009; 951 citations) for IPSS survival model guiding transplant timing, and Barbui et al. (2011; 825 citations) for ELN management including allo-SCT indications.
Recent Advances
Study Khoury et al. (2022; 3500 citations) 5th WHO edition for updated MPN entities relevant to transplantation, and Barbui et al. (2018; 537 citations) revised ELN recommendations on high-risk therapy.
Core Methods
IPSS/DIPSS prognostic scoring (Passamonti et al., 2009); HLA-matched donor selection and reduced-intensity conditioning per ELN (Barbui et al., 2011); molecular profiling of JAK2/MPL/ASXL1 for risk (Tefferi, 2010).
How PapersFlow Helps You Research Allogeneic Stem Cell Transplantation in Myeloproliferative Neoplasms
Discover & Search
Research Agent uses searchPapers('allogeneic stem cell transplantation myeloproliferative neoplasms') to retrieve Passamonti et al. (2009; 951 citations), then citationGraph reveals forward citations on IPSS for transplant risk, and findSimilarPapers expands to Barbui et al. (2011) guidelines.
Analyze & Verify
Analysis Agent applies readPaperContent on Arber et al. (2016) WHO classification to extract MPN transformation criteria, verifyResponse with CoVe cross-checks survival data against Passamonti et al. (2009), and runPythonAnalysis computes IPSS scores from patient data using pandas for eligibility prediction with GRADE B evidence.
Synthesize & Write
Synthesis Agent detects gaps in allo-SCT outcomes for ASXL1-mutated MPNs (Tefferi, 2010), flags contradictions between 2008/2016 WHO revisions (Vardiman et al., 2009; Arber et al., 2016); Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 20+ refs, latexCompile for PDF, and exportMermaid for transplant outcome flowcharts.
Use Cases
"Analyze survival curves from IPSS in myelofibrosis patients eligible for allo-SCT"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib replot Passamonti 2009 curves) → GRADE-verified Kaplan-Meier plots with risk ratios.
"Draft LaTeX review on donor selection in MPN transplantation per ELN guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText (insert Barbui 2011 tables) → latexSyncCitations → latexCompile → peer-reviewed PDF with GvL diagrams.
"Find code for JAK2 mutation analysis in post-transplant MPN monitoring"
Research Agent → paperExtractUrls (Tefferi 2010) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis sandbox for variant calling pipeline.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ MPN allo-SCT papers) → citationGraph → DeepScan (7-step: extract IPSS data, CoVe verify, Python survival modeling). Theorizer generates hypotheses on GvL in JAK2V617F MPNs from Mullally et al. (2010) + Passamonti (2009), outputting testable models via exportMermaid.
Frequently Asked Questions
What defines allogeneic SCT in MPNs?
Allo-SCT replaces patient hematopoietic cells with donor stem cells post-conditioning, curative for high-risk MPNs transforming to AML (Barbui et al., 2011).
What methods assess transplant eligibility?
IPSS/DIPSS models using age >65, Hb <10g/dL, blasts ≥1% predict poor survival warranting allo-SCT (Passamonti et al., 2009; 951 citations).
What are key papers?
Passamonti et al. (2009; 951 citations) on IPSS; Barbui et al. (2011; 825 citations) ELN recommendations; Arber et al. (2016; 9991 citations) WHO MPN classification.
What open problems exist?
Optimizing reduced-intensity conditioning and predicting GvL in molecularly-defined MPN subsets like ASXL1-mutated cases lack prospective data (Tefferi, 2010).
Research Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Allogeneic Stem Cell Transplantation in Myeloproliferative Neoplasms with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers